Apollo Hospitals Enterprise Limited has informed the Exchange about Scheme of Arrangement

Demerger ratio announcedScheme filed with the NCLTListed-company acquisitionMarquee JV announcedStrategic Transactions View source PDF Explain this filing

APOLLOHOSP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.7%Reaction day

₹7238.00

prior close

₹7475.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.1%+3.6% vs market

Hospital peers, median of 21sector-0.3%+4.0% vs sector

On the reaction day the stock moved 3.6 pts more than Nifty 100 and 4.0 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+1.0

15m

+1.3

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.7+0.1+3.6-0.3+4.0

Next day

+3.0-0.3+3.3-0.2+3.3

+4.6-0.5+5.1+0.5+4.2

+4.3-0.3+4.6+1.8+2.5

+5.0-0.2+5.2+2.1+2.9

+4.4-0.1+4.4+1.7+2.7

+1.6-0.6+2.2+0.9+0.7

15d

+0.1-1.7+1.8+2.4-2.2

+1.7-3.8+5.5+5.6-4.0

+5.8-3.5+9.3+3.2+2.6

+3.1-2.4+5.5+2.5+0.6

UpDownMarket · Nifty 100Sector · Hospital peers, median of 21Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Apollo Hospitals' board has approved a composite scheme on June 30, 2025 that involves three steps: (1) demerger of its omni-channel pharmacy and digital health business (Apollo 24/7 platform, telehealth) into a new wholly-owned subsidiary called Apollo Healthtech Limited (NewCo), (2) merger of its material subsidiary Apollo HealthCo Limited (AHL) into NewCo, and (3) merger of Keimed Private Limited (a leading wholesale pharma distributor) into NewCo. Under the demerger, AHEL shareholders will receive 195.2 shares of NewCo for every 100 shares of AHEL held. The combined NewCo had FY25 revenue of approximately ₹16,300 crore, with a target of ₹25,000 crore by FY27 and ~7% EBITDA margins. AHEL will retain a 15% stake in NewCo, which is expected to list on NSE and BSE within 18-21 months, subject to NCLT, SEBI, IRDAI, CCI, shareholder, and creditor approvals.

Likely market impact

This restructuring allows AHEL shareholders to directly participate in the value of the combined pharmacy distribution and digital health business, eliminating any holding-company discount. The new entity will become Indian Owned and Controlled and aims to consolidate 100% of Apollo Pharmacies by acquiring the remaining 74.5% stake in AMPL, creating a unified, listed omni-channel healthcare platform.